Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis — Probabli.AI
AI-powered analysis for IOVA (Iovance Biotherapeutics, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $14.45 · Market cap: $5.0B · AI outlook: Bullish
Iovance Biotherapeutics is a high-growth biotech company focused on cell-based cancer therapies, primarily TIL therapies. The company has shown significant potential with FDA fast track status and strategic partnerships boosting its growth outlook. Despite ongoing challenges including patent disputes and regulatory hurdles, the company is well-positioned for significant advancements in…
Probabilistic 1-Year Outlook
- Bull 40% · Neutral 35% · Bear 25%
- 1-year price estimates — P10: $10 / P50: $16 / P90: $25
- Iovance Biotherapeutics is currently in a strong growth position with an 8260% revenue estimate growth primarily due to its treatment products gaining fast track FDA approval. Despite a negative average EPS surprise and…
5-Year Outlook
- Bull 50% · Neutral 30% · Bear 20%
- 5-year price estimates — P10: $15 / P50: $30 / P90: $60
SWOT Highlights
- Strength: FDA fast track designation for TIL therapy
- Strength: High revenue growth potential
- Risk: Negative earnings surprise trend
- Risk: Regulatory challenges causing trial delays
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
10 Wall Street analysts rate IOVA a BUY with a mean price target of $12.44.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
IOVA forecast details · IOVA sentiment details · IOVA insider activity
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.